The trial, sponsored by Albert Einstein College of Medicine, aimed to evaluate the safety and efficacy of lenalidomide as a maintenance therapy for elderly patients with acute myeloid leukemia (AML) post-autologous stem cell transplant. However, the study was terminated due to low patient accrual, indicating potential challenges in patient recruitment for this demographic. The market for AML therapies is competitive, with several established treatments and emerging therapies. The failure to complete this trial may impact the sponsor's position in the AML treatment landscape and could influence future investment decisions or collaborations in this area.